183 related articles for article (PubMed ID: 29129003)
1. Chelation Therapy as a Cardiovascular Therapeutic Strategy: the Rationale and the Data in Review.
Mathew RO; Schulman-Marcus J; Nichols EL; Newman JD; Bangalore S; Farkouh M; Sidhu MS
Cardiovasc Drugs Ther; 2017 Dec; 31(5-6):619-625. PubMed ID: 29129003
[TBL] [Abstract][Full Text] [Related]
2. EDTA Chelation Therapy to Reduce Cardiovascular Events in Persons with Diabetes.
Ouyang P; Gottlieb SH; Culotta VL; Navas-Acien A
Curr Cardiol Rep; 2015 Nov; 17(11):96. PubMed ID: 26364188
[TBL] [Abstract][Full Text] [Related]
3. Chelation therapy in cardiovascular disease: an update.
Sultan S; Murarka S; Jahangir A; Mookadam F; Tajik AJ; Jahangir A
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):843-854. PubMed ID: 28597699
[TBL] [Abstract][Full Text] [Related]
4. Chelation therapy in the treatment of cardiovascular diseases.
Ibad A; Khalid R; Thompson PD
J Clin Lipidol; 2016; 10(1):58-62. PubMed ID: 26892121
[TBL] [Abstract][Full Text] [Related]
5. Chelation therapy for cardiovascular disease. Review and commentary.
Lewin MR
Tex Heart Inst J; 1997; 24(2):81-9. PubMed ID: 9205980
[No Abstract] [Full Text] [Related]
6. Potential Role of Metal Chelation to Prevent the Cardiovascular Complications of Diabetes.
Calderon Moreno R; Navas-Acien A; Escolar E; Nathan DM; Newman J; Schmedtje JF; Diaz D; Lamas GA; Fonseca V
J Clin Endocrinol Metab; 2019 Jul; 104(7):2931-2941. PubMed ID: 30869793
[TBL] [Abstract][Full Text] [Related]
7. Heavy Metals, Cardiovascular Disease, and the Unexpected Benefits of Chelation Therapy.
Lamas GA; Navas-Acien A; Mark DB; Lee KL
J Am Coll Cardiol; 2016 May; 67(20):2411-2418. PubMed ID: 27199065
[TBL] [Abstract][Full Text] [Related]
8. Chelation therapy and cardiovascular disease: connecting scientific silos to benefit cardiac patients.
Peguero JG; Arenas I; Lamas GA
Trends Cardiovasc Med; 2014 Aug; 24(6):232-40. PubMed ID: 25106084
[TBL] [Abstract][Full Text] [Related]
9. Metal chelation therapy in rheumathoid arthritis: a case report. Successful management of rheumathoid arthritis by metal chelation therapy.
Bamonti F; Fulgenzi A; Novembrino C; Ferrero ME
Biometals; 2011 Dec; 24(6):1093-8. PubMed ID: 21655943
[TBL] [Abstract][Full Text] [Related]
10. The effect of EDTA-based chelation on patients with diabetes and peripheral artery disease in the Trial to Assess Chelation Therapy (TACT).
Ujueta F; Arenas IA; Escolar E; Diaz D; Boineau R; Mark DB; Golden P; Lindblad L; Kim H; Lee KL; Lamas GA
J Diabetes Complications; 2019 Jul; 33(7):490-494. PubMed ID: 31101487
[TBL] [Abstract][Full Text] [Related]
11. A TACTful reappraisal of chelation therapy in cardiovascular disease.
Sidhu MS; Saour BM; Boden WE
Nat Rev Cardiol; 2014 Mar; 11(3):180-3. PubMed ID: 24343569
[TBL] [Abstract][Full Text] [Related]
12. Chronic Toxic Metal Exposure and Cardiovascular Disease: Mechanisms of Risk and Emerging Role of Chelation Therapy.
Aneni EC; Escolar E; Lamas GA
Curr Atheroscler Rep; 2016 Dec; 18(12):81. PubMed ID: 27822681
[TBL] [Abstract][Full Text] [Related]
13. EDTA chelation reappraisal following new clinical trials and regular use in millions of patients: review of preliminary findings and risk/benefit assessment.
Born T; Kontoghiorghe CN; Spyrou A; Kolnagou A; Kontoghiorghes GJ
Toxicol Mech Methods; 2013 Jan; 23(1):11-7. PubMed ID: 22991933
[TBL] [Abstract][Full Text] [Related]
14. Why the NIH Trial to Assess Chelation Therapy (TACT) should be abandoned.
Atwood KC; Woeckner E; Baratz RS; Sampson WI
Medscape J Med; 2008 May; 10(5):115. PubMed ID: 18596934
[TBL] [Abstract][Full Text] [Related]
15. Natural antidotes and management of metal toxicity.
Amadi CN; Offor SJ; Frazzoli C; Orisakwe OE
Environ Sci Pollut Res Int; 2019 Jun; 26(18):18032-18052. PubMed ID: 31079302
[TBL] [Abstract][Full Text] [Related]
16. Heavy Metal Toxicity in Chronic Renal Failure and Cardiovascular Disease: Possible Role for Chelation Therapy.
Glicklich D; Shin CT; Frishman WH
Cardiol Rev; 2020; 28(6):312-318. PubMed ID: 32040019
[TBL] [Abstract][Full Text] [Related]
17. Baseline characteristics including blood and urine metal levels in the Trial to Assess Chelation Therapy 2 (TACT2).
Navas-Acien A; Santella RM; Joubert BR; Huang Z; Lokhnygina Y; Ujueta F; Gurvich I; LoIacono NJ; Ravalli F; Ward CD; Jarrett JM; Salazar AL; Boineau R; Jones TLZ; Mark DB; Newman JD; Nathan DM; Anstrom KJ; Lamas GA
Am Heart J; 2024 Jul; 273():72-82. PubMed ID: 38621575
[TBL] [Abstract][Full Text] [Related]
18. Design of the Trial to Assess Chelation Therapy (TACT).
Lamas GA; Goertz C; Boineau R; Mark DB; Rozema T; Nahin RL; Drisko JA; Lee KL
Am Heart J; 2012 Jan; 163(1):7-12. PubMed ID: 22172430
[TBL] [Abstract][Full Text] [Related]
19. The trial to assess chelation therapy 2 (TACT2): Rationale and design.
Lamas GA; Anstrom KJ; Navas-Acien A; Boineau R; Kim H; Rosenberg Y; Stylianou M; Jones TLZ; Joubert BR; Santella RM; Escolar E; Aude YW; Fonseca V; Elliott T; Lewis EF; Farkouh ME; Nathan DM; Mon AC; Gosnell L; Newman JD; Mark DB;
Am Heart J; 2022 Oct; 252():1-11. PubMed ID: 35598636
[TBL] [Abstract][Full Text] [Related]
20. Letter to the editor concerning article "Design of the Trial to Assess Chelation Therapy (TACT)".
Ernst E
Am Heart J; 2012 Dec; 164(6):e23; author reply e25. PubMed ID: 23194497
[No Abstract] [Full Text] [Related]
[Next] [New Search]
